In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PharmaMar, S.A.

http://www.pharmamar.com/

Latest From PharmaMar, S.A.

Going Global Gets Stuck, Chinese Drug Makers CRL Show What Not To Do

Chinese drug makers have more to lament and plenty to learn from as Junshi, HutchMed follow Innovent Bio with FDA rejections. A holistic not opportunistic approach is needed, one ex-FDA expert suggests.

Drug Review Regulation

Lilly To Decide Next Steps After Formal FDA 'Nay' For First Chinese PD-1

The official verdict is in for sintilimab and the results are not surprising. But some view the setback for "Made In China" innovation as a chance to reflect and move forward.

Regulation Complete Response Letters

Younger Females' Cancer Incidence Increases Significantly In China

Latest data show a worrying public health trend that remains the top health concern in China despite surging COVID infections.

China Cancer

A Dark Horse Five Years In The Making: Legend Gains First Global Approval

Nanjing Legend gains FDA approval for its BCMA cell therapy, the second to go to market in the US marks a win for true innovators from China, not cheaper but similar products, some say.

China Cancer
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
  • Other Names / Subsidiaries
    • Grupo Zeltia
    • PharmaMar
    • Zeltia Group
UsernamePublicRestriction

Register